Prostate Cancer

Share this page:

Early stage disease

Review of Specific Treatments

For early stage lesions in healthy patients (T1-2, N0, M0), definitive resection, permanent source brachytherapy, high dose rate (HDR) brachytherapy, 3D conformal radiotherapy (3DCRT), intensity modulated radiotherapy (IMRT), combined radiotherapy modalities such as 3DCRT plus HDR brachytherapy, or combined androgen suppressive therapy plus radiotherapy are all accepted as reasonable therapeutic alternatives (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15).

Radical prostatectomy is the only method to date with a proven survival advantage compared with watchful waiting in early stage prostate cancer patients (2), causing many practitioners to consider it the “gold standard,” against which other treatments are compared. To complicate the analysis though, other studies have found no significant difference in disease-free survival between radical prostatectomy, high dose 3DCRT, or permanent source brachytherapy (16,17). Yet another study has proven PSA-disease free survival equivalence between HDR brachytherapy and permanent source brachytherapy (9).

In other words, a number of treatment approaches appear to have similar curative potential against localized disease, with no single modality clearly proven superior to the others.

prostate cancer

Written by Donald B. Fuller, M.D. – Radiation Oncologist

Central San Diego

5395 Ruffin Road, Suite 103
San Diego, CA 92123
(858) 505-4100
(800) 470-1256

North County San Diego

477 N. El Camino Real, Suite D-101
Encinitas, CA. 92024
(760) 230-6706
(800) 470-1256

2010 © All Rights Reserved | www.sdcyberknife.com